Cogent Biosciences Inc (COGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has a cash flow conversion efficiency ratio of -0.124x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-79.11 Million) by net assets ($636.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cogent Biosciences Inc (COGT) net asset quality to measure how much of total assets are equity-financed.
Cogent Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COGT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Cogent Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cogent Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung Engineering
KO:028050
|
-0.059x |
|
Compagnie du Cambodge
PA:CBDG
|
0.004x |
|
YTL Corporation Bhd
KLSE:4677
|
0.021x |
|
Churchill Downs Incorporated
NASDAQ:CHDN
|
0.091x |
|
Glanbia PLC
IR:GL9
|
0.021x |
|
Ameris Bancorp
NYSE:ABCB
|
0.063x |
|
SmartSens Technology (Shanghai) Co. Ltd. A
SHG:688213
|
N/A |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Cogent Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Cogent Biosciences Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see COGT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $636.37 Million | $-264.44 Million | -0.416x | +48.75% |
| 2024-12-31 | $256.29 Million | $-207.79 Million | -0.811x | -36.06% |
| 2023-12-31 | $257.80 Million | $-153.62 Million | -0.596x | -28.45% |
| 2022-12-31 | $255.74 Million | $-118.64 Million | -0.464x | -69.09% |
| 2021-12-31 | $214.18 Million | $-58.76 Million | -0.274x | -79.59% |
| 2020-12-31 | $234.67 Million | $-35.85 Million | -0.153x | +88.31% |
| 2019-12-31 | $31.76 Million | $-41.51 Million | -1.307x | -142.32% |
| 2018-12-31 | $60.23 Million | $-32.49 Million | -0.539x | +40.91% |
| 2017-12-31 | $28.30 Million | $-25.84 Million | -0.913x | -156.53% |
| 2016-12-31 | $52.39 Million | $-18.64 Million | -0.356x | -239.62% |
| 2015-12-31 | $69.52 Million | $17.72 Million | 0.255x | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more